Non-specific effects of vaccinations in high-income settings: How to address the issue?

Abstract:

:"Non-specific effects" of vaccines go beyond the specific protective effects against the targeted diseases. They, if real, could theoretically be beneficial, neutral or negative. This article intends to answer the following questions: Do the non-specific effects of vaccines exist? Almost certainly yes, and they can be important in low-income countries Are non-specific effects also present in high-income countries? At least to some extent, it seems quite logical Can non-specific effects be systematically identified by the current systems of side effects/unintended reactions monitoring? Most likely not Could the Institute of Medicine proposals and some ongoing attempts solve the issue? It seems unlikely Could there be better, feasible and ethically acceptable ways to achieve the aforementioned objective? A proposal is presented about this issue, with the potential both to solve the problem with the most valid methods, and to overcome the ethical problems that have so far precluded the adoption of RCTs to study possible vaccine non-specific effects, monitored by long follow-up.

journal_name

Hum Vaccin Immunother

authors

Donzelli A,Schivalocchi A,Giudicatti G

doi

10.1080/21645515.2018.1502520

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

2904-2910

issue

12

eissn

2164-5515

issn

2164-554X

journal_volume

14

pub_type

杂志文章
  • Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine.

    abstract::Timely vaccine supply is critical during influenza pandemics but is impeded by current virus-based manufacturing methods. The 2009 H1N1/2009pdm 'swine flu' pandemic reinforced the need for innovation in pandemic vaccine design. We report on insights gained during rapid development of a pandemic vaccine based on recomb...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/21645515.2017.1279765

    authors: Honda-Okubo Y,Rajapaksha H,Sajkov D,Gordon D,Cox MMJ,Petrovsky N

    更新日期:2017-06-03 00:00:00

  • Are children's vitamin D levels and BMI associated with antibody titers produced in response to 2014-2015 influenza vaccine?

    abstract:BACKGROUND:Vitamin D is an immunomodulating hormone, which has been associated with susceptibility to infectious diseases. METHODS:Serum vitamin D levels in 135 children ages 3-17 y were measured at baseline and hemagglutinin influenza antibody titers were measured pre- and 21 d post influenza vaccination with live at...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1299837

    authors: Lin CJ,Martin JM,Cole KS,Zimmerman RK,Susick M,Moehling KK,Levine MZ,Spencer S,Flannery B,Nowalk MP

    更新日期:2017-07-03 00:00:00

  • Introduction of a new Rotavirus vaccine: Initial results of uptake and impact on laboratory confirmed cases in Anglia and Essex, United Kingdom, July 2015.

    abstract::Rotavirus gastroenteritis accounts for an estimated 130,000 GP consultations and 13,000 hospitalisations for children under 5 y old each year in England and Wales. In July 2013, an oral live attenuated rotavirus vaccine (Rotarix®) was introduced into the UK infant immunisation program as a 2 dose schedule at 2 and 3 m...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1108501

    authors: Inns T,Trindall A,Dunling-Hall S,Shankar AG

    更新日期:2016-04-02 00:00:00

  • Immunization of children with secondary immunodeficiency.

    abstract::The main causes of secondary immunodeficiency at a pediatric age include infectious diseases (mainly HIV infection), malignancies, haematopoietic stem cell or solid organ transplantation and autoimmune diseases. Children with secondary immunodeficiency have an increased risk of severe infectious diseases that could be...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1039208

    authors: Esposito S,Prada E,Lelii M,Castellazzi L

    更新日期:2015-01-01 00:00:00

  • Influenza vaccine effectiveness among healthcare workers in comparison to hospitalized patients: A 2004-2009 case-test, negative-control, prospective study.

    abstract::The objective of this study was to calculate Vaccine Effectiveness (VE) in healthcare workers (HCW) and to compare VE between patients and HCW. A case-control investigation based on the prospective study was conducted between 2004 and 2009 in a teaching hospital. All HCW with influenza-like illness (ILI) from particip...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1079677

    authors: Vanhems P,Baghdadi Y,Roche S,Bénet T,Regis C,Lina B,Robert O,Voirin N,Ecochard R,Amour S

    更新日期:2016-01-01 00:00:00

  • Persistence of immune memory among adults with normal and high antibody response to primary hepatitis B vaccination: Results from a five-year follow-up study in China.

    abstract::Immune memory after hepatitis B vaccination among adults is still under investigation. In this study, adults who had normal and high antibody response to the primary series of hepatitis B vaccination (HepB) were followed up at 5 years after the primary immunization. A booster dose was given to those who had low hepati...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1477911

    authors: Wu W,Lv J,Liu J,Yan B,Feng Y,Xu A,Zhang L

    更新日期:2018-01-01 00:00:00

  • Intravescical instillation of Calmette-Guérin bacillus and COVID-19 risk.

    abstract::It has been theorized that Calmette-Guérin bacillus may prevent or reduce the severity of COVID-19 through a nonspecific stimulation of the immune system. A preliminary assessment of SARS-CoV-2 infection rates and outcomes among 2803 individuals affected with high risk non-muscle-invasive bladder cancer and treated wi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1805994

    authors: Fedeli U,Porreca A,Colicchia M,Schievano E,Artibani W,Biasio LR,Palù G

    更新日期:2020-09-03 00:00:00

  • Patient characteristics of Medicare beneficiaries who report not getting influenza and pneumococcal vaccinations, 2001-2013.

    abstract::Background: Despite long standing recommendations of pneumococcal and influenza vaccination for adults age 65 years and older and wide-spread availability to vaccination services, vaccination coverage in the United states is low. We sought to explore reasons patients reportedly did not receive these vaccines.Methods: ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1688033

    authors: Shen AK,Warnock R,Selna W,Chu S,Kelman JA

    更新日期:2020-05-03 00:00:00

  • Regional variations in HPV vaccination among 9-17 year old adolescent females from the BRFSS, 2008-2010.

    abstract::Human papillomavirus (HPV) vaccine uptake among 18-26 y old women varies by geographic region in the US. However, little is known about regional variations in vaccination among girls who are in the vaccine's targeted age groups. Regional variation in HPV vaccination among female adolescents (9-17 y old) was examined u...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/21645515.2014.980202

    authors: Hirth JM,Rahman M,Smith JS,Berenson AB

    更新日期:2014-01-01 00:00:00

  • Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules.

    abstract::In tick-borne encephalitis (TBE)-endemic regions, long-term vaccination programs are efficient in preventing the disease. A booster dose of a polygeline-free inactivated TBE vaccine (Encepur Adults, GSK), administered approximately 3 years post-primary vaccination according to 1 of 3 licensed vaccination schedules in ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1700712

    authors: Costantini M,Callegaro A,Beran J,Berlaimont V,Galgani I

    更新日期:2020-09-01 00:00:00

  • Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.

    abstract::One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/21645515.2017.1309486

    authors: Berry AA,Abu-Elyazeed R,Diaz-Perez C,Mufson MA,Harrison CJ,Leonardi M,Twiggs JD,Peltier C,Grogg S,Carbayo A,Shapiro S,Povey M,Baccarini C,Innis BL,Henry O

    更新日期:2017-07-03 00:00:00

  • Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model.

    abstract::Regulatory T cells (Tregs) play a crucial role in the control of the initiation and progression of type 1 diabetes (T1D). Various immunological interventions including those to ex vivo expansion Tregs transfer, in vivo induction of peripherally derived Treg (pTreg) have been considered as promising approaches for T1D ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1616504

    authors: Zhou X,Zhang S,Yu F,Zhao G,Geng S,Yu W,Wang XY,Wang B

    更新日期:2020-01-01 00:00:00

  • Purification and immunogenicity of hemagglutinin from highly pathogenic avian influenza virus H5N1 expressed in Nicotiana benthamiana.

    abstract::Highly pathogenic avian influenza (HPAI) H5N1 is an ongoing global health concern due to its severe sporadic outbreaks in Asia, Africa and Europe, which poses a potential pandemic threat. The development of safe and cost-effective vaccine candidates for HPAI is considered the best strategy for managing the disease and...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1264783

    authors: Pua TL,Chan XY,Loh HS,Omar AR,Yusibov V,Musiychuk K,Hall AC,Coffin MV,Shoji Y,Chichester JA,Bi H,Streatfield SJ

    更新日期:2017-02-01 00:00:00

  • On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012.

    abstract::High-dose inactivated, influenza vaccine was licensed by the FDA in December 2009 for adults aged 65 y and older. The ACIP did not issue or state a preference for a specific vaccine in the elderly population. The extent of its on-label and off-label use is unknown. Using the MarketScan Commercial Claims and Encounters...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1011026

    authors: McGrath LJ,Brookhart MA

    更新日期:2015-01-01 00:00:00

  • Is Italian population protected from Poliovirus? Results of a seroprevalence survey in Florence, Italy.

    abstract:OBJECTIVES:Periodical assessments of population susceptibility to polioviruses (PV) is essential for evaluating population protection and planning appropriate vaccination strategies. The aim of the current work was to assess serological protective titers against all three polioviruses in the general population of Flore...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1475812

    authors: Giammanco GM,Bechini A,Urone N,Bonura F,Li Muli S,De Grazia S,Bellini I,Tiscione E,Boccalini S,Nastasi A

    更新日期:2018-01-01 00:00:00

  • Incomplete vaccination and associated factors among children aged 12-23 months in South Africa: an analysis of the South African demographic and health survey 2016.

    abstract:BACKGROUND:Socioeconomic and health inequalities remain a huge problem in post-apartheid South Africa. Despite substantial efforts at ensuring universal access to vaccines, many children remain under-vaccinated in the country. This study aimed to assess the prevalence and factors associated with incomplete vaccination ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1791509

    authors: Ndwandwe D,Nnaji CA,Mashunye T,Uthman OA,Wiysonge CS

    更新日期:2020-07-23 00:00:00

  • Novel nanoparticle vaccines for Listeriosis.

    abstract::In recent years, nanomedicine has transformed many areas of traditional medicine, and enabled fresh insights into the prevention of previously difficult to treat diseases. An example of the transformative power of nanomedicine is a recent nano-vaccine against listeriosis, a serious bacterial infection affecting not on...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1063756

    authors: Calderon-Gonzalez R,Marradi M,Garcia I,Petrovsky N,Alvarez-Dominguez C

    更新日期:2015-01-01 00:00:00

  • Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain).

    abstract::The objectives of this study were to estimate incidence density rates (IDR) of herpes zoster (HZ) and to analyze the association with sociodemographic characteristics and selected chronic medical conditions. The study cohort consisted of the adult population included in the Public Health System of the Autonomous Commu...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.28620

    authors: Esteban-Vasallo MD,Domínguez-Berjón MF,Gil-Prieto R,Astray-Mochales J,Gil de Miguel A

    更新日期:2014-01-01 00:00:00

  • Product review: avelumab, an anti-PD-L1 antibody.

    abstract::Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor mi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1551671

    authors: Collins JM,Gulley JL

    更新日期:2019-01-01 00:00:00

  • Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic.

    abstract::A novel coronavirus (2019-nCov) emerged in China, at the end of December 2019 which posed an International Public Health Emergency, and later declared as a global pandemic by the World Health Organization (WHO). The International Committee on Taxonomy of Viruses (ICTV) named it SARS-CoV-2 (Severe Acute Respiratory Syn...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1824497

    authors: Siddique R,Bai Q,Shereen MA,Nabi G,Han G,Rashid F,Ahmed S,Benzhanova A,Xue M,Khan S

    更新日期:2020-10-16 00:00:00

  • Application of a novel nanoemulsion adjuvant for rabies vaccine which stabilizes a Krebs cycle intermediate (SDH) in an animal model.

    abstract::Rabies is the most lethal zoonotic, vaccine-preventable viral disease in the world. Its treatment is complicated by insufficient vaccine supply and the requirement for four to five repeated injections, as commercially available inactivated rabies lack adjuvant and have low immunogenicity. In this study, we focused on ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1531966

    authors: Ze L,Zonglin L,Ya'Nan W,Shaohui S,Huijuan Y,Wei C,Li W,Liao G

    更新日期:2019-01-01 00:00:00

  • A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).

    abstract::The licensed meningococcal serogroup B vaccine, 4CMenB (Bexsero(®)), contains recombinant membrane proteins (rMenB) and outer membrane vesicles (OMV) of the New Zealand serogroup B strain. We investigated whether reducing the OMV and/or protein content influences 4CMenB immunogenicity and reactogenicity in healthy two...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.4161/hv.29218

    authors: Esposito S,Prymula R,Zuccotti GV,Xie F,Barone M,Dull PM,Toneatto D

    更新日期:2014-01-01 00:00:00

  • Narrowing the policy gap: lessons from years 2 and 3 of the British Columbia influenza prevention policy.

    abstract::Influenza can be potentially fatal to vulnerable populations, particularly those in the hospital. Canada's National Advisory Committee on Immunization recommends that health-care workers (HCW) be immunized against influenza partly to avoid infecting high-risk populations. However, influenza immunization rates among HC...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1692561

    authors: Di Castri AM,Halperin DM,McPherson CM,Nunn A,Farrar-Muir H,Kwong JC,Henry B

    更新日期:2020-06-02 00:00:00

  • Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.

    abstract::Vaginal and vulvar cancers do not account for a large proportion of gynecologic malignancies but their impact is significant. Both vaginal and vulvar lesions have precursors and display levels of dysplasia before progression to invasive disease. Human Papillomavirus (HPV) is a known causative agent of such dysplasia a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1147634

    authors: Buchanan TR,Graybill WS,Pierce JY

    更新日期:2016-06-02 00:00:00

  • Impact of serogroup A meningococcal conjugate vaccine for Africa.

    abstract::The introduction of a serogroup A meningococcal conjugate vaccine in the African meningitis belt has been a remarkable success. Meningitis due to the serogroup A meningococcus, previously responsible for most epidemics, has fallen by 99% in vaccinated countries. Success must, however, not distract from the continuing ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1412022

    authors: Stuart JM

    更新日期:2018-05-04 00:00:00

  • Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence.

    abstract::Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publications describing antib...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1735224

    authors: Chilson E,Scott DA,Schmoele-Thoma B,Watson W,Moran MM,Isturiz R

    更新日期:2020-11-01 00:00:00

  • Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine.

    abstract::Purpose: Gaps remain in the public's knowledge of the human papillomavirus (HPV). We assessed racial/ethnic and gender disparities in knowledge and awareness of HPV and the HPV vaccine among US adults. METHODS:Data from the Health Information National Trends Survey 4 Cycle 3 (September - December 2013) and Cycle 4 (A...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1363133

    authors: Adjei Boakye E,Tobo BB,Rojek RP,Mohammed KA,Geneus CJ,Osazuwa-Peters N

    更新日期:2017-11-02 00:00:00

  • ASVAC2019: 7th Asian Vaccine Conference.

    abstract::The 7th Asian Vaccine Conference (ASVAC 2019) was held in Yangon, Myanmar from 13 to 15, September 2019. It brought together stakeholders in the field of vaccination to address challenges and issues relevant to clinical practice and immunization programs in the region. The conference themed "Immunization: sustaining h...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1695460

    authors: Linn K,Bravo L,Goh DYT,Nelson EAS

    更新日期:2020-07-02 00:00:00

  • The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority stud

    abstract::Immunogenicity and safety of ACWY-TT compared with licensed ACWY polysaccharide vaccine (MenPS) in healthy adults, and lot-to-lot consistency of three ACWY-TT lots were evaluated in a phase 3, open, controlled study. Adults aged 18-55 y were randomized to receive ACWY-TT (one of three lots) or MenPS. Serum bactericida...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/hv.20211

    authors: Dbaibo G,Macalalad N,Aplasca-De Los Reyes MR,Dimaano E,Bianco V,Baine Y,Miller J

    更新日期:2012-07-01 00:00:00

  • Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia.

    abstract::How countries, particularly low- and middle-income economies, should pay the coronavirus disease 2019 (COVID-19) vaccine is an important and understudied issue. We undertook an online survey to measure the willingness-to-pay (WTP) for a COVID-19 vaccine and its determinants in Indonesia. The WTP was assessed using a s...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1819741

    authors: Harapan H,Wagner AL,Yufika A,Winardi W,Anwar S,Gan AK,Setiawan AM,Rajamoorthy Y,Sofyan H,Vo TQ,Hadisoemarto PF,Müller R,Groneberg DA,Mudatsir M

    更新日期:2020-12-01 00:00:00